KPMG's Guidance for Big Pharma on Psychedelics & Pennsylvania's Policy Pivot
www.thetripreport.com
Today, we’re looking at two related, very related, themes. Does Big Pharma have any interest in psychedelics? Are psychedelics-as-medicines an opportunity to reimagine how drug development is funded, studied and approved? Related to the second point, I am developing a strong—but potentially naive— intuition about an approach to state policy reform, which I begin to outline in the last section of this post. I would be keen to hear comments and feedback!
KPMG's Guidance for Big Pharma on Psychedelics & Pennsylvania's Policy Pivot
KPMG's Guidance for Big Pharma on…
KPMG's Guidance for Big Pharma on Psychedelics & Pennsylvania's Policy Pivot
Today, we’re looking at two related, very related, themes. Does Big Pharma have any interest in psychedelics? Are psychedelics-as-medicines an opportunity to reimagine how drug development is funded, studied and approved? Related to the second point, I am developing a strong—but potentially naive— intuition about an approach to state policy reform, which I begin to outline in the last section of this post. I would be keen to hear comments and feedback!